aethlon medical, inc. (otcbb: aemd)
Post on 23-Jun-2015
273 Views
Preview:
TRANSCRIPT
Trading Symbol: AEMD
Presenter:
James A. Joyce
Chairman and CEO
This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when new products are successfully developed and introduced by the Company, market acceptance of current or new products, regulatory delays, manufacturing delays, and other risks which may be detailed in Aethlon Medical’s SEC filings.
HOMELAND DEFENSE CONFERENCEWASHINGTON, DC. MARCH 30, 2004
Trading Symbol: AEMD
Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viruses and toxins in the blood.
“...at the forefront of developing promising new treatments...“ (The Washington Times)
Trading Symbol: AEMD
The HemopurifierTM
Hemodialysis
Affinity Chromatography
An Expansive Platform TechnologyConverging Established Principles
Trading Symbol: AEMD
HemopurifierTM Advantages
Mimics Immune Response
Antibody Immobilization
Fusion/Entry Inhibitor
Multiple Disease Treatment
Established Infrastructure
Trading Symbol: AEMD
HemopurifierTM Markets
Biological Weapons
HIV/AIDS
Hepatitis-C (HCV)
Trading Symbol: AEMD
Published Human Blood Studies
55%+ removal of HIV in three hours.
85%+ removal of HIV in twelve hours.
90% removal of gp120 in one hour.
58% removal of HCV in two hours.
Trading Symbol: AEMD
Biological Weapon Targets
CDC CATEGORY “A” AGENTS Smallpox Viruses
Anthrax Bacterium
Botulinum Toxin
Hemorrhagic Fevers
Ebola
Marburg
Septic Shock Mediators
Genetically Engineered
Trading Symbol: AEMD
Bioterrorism Challenges
Vast Number of Targets
Genetic Engineering
Vaccine & Drug Limitations
Pathogens are Inexpensive & Accessible
Easy to Deliver
Trading Symbol: AEMD
Hemopurifier Advantages
Adjunctive
Sole Solution
Rapid Development & Deployment
Addresses Military & Civilian Requirements
Trading Symbol: AEMD
National Center for Biodefense
U.S. Military - Countermeasures Against Biological Weapons
Improves Access to Government Grants & Contracts
Increases Scientific Resources, Advocates Charles Bailey, MD.
Ken Alibek, MD.
Trading Symbol: AEMD
The Aethlon Science Team
Trading Symbol: AEMD
Richard Tullis, Ph.D.
Developer of Infectious Disease and Biowarfare Hemopurifiers. Inventor and original patent holder of Antisense, and related DNA
synthesis technologies.
Co-founder and Director of Research of Molecular Biosystems (NYSE).
Founder of Synthetic Genetics, Inc., and Syngen Research, Inc.
Aethlon Chief Scientific Officer, Director
Trading Symbol: AEMD
Kenneth Michael, Ph.D.
Founder, Past President & Chairman of The Regulatory Affairs Professionals Society (RAPS), an 8000 member International
Regulatory Affairs Organization. Director of Regulatory Affairs at Siemens Medical Systems.
Regulatory and Clinical Affairs Advisor
Trading Symbol: AEMD
Nathan W. Levin, MD
Medical and Research Director of the Renal Research Institute, LLC.
Professor of Clinical Medicine at the Albert Einstein College of Medicine.
SCIENCE ADVISORY BOARD / Dialysis
Trading Symbol: AEMD
Claudio Ronco, MD
Director of the Dialysis and Renal Transplantation at St. Bartolo Hospital in Vicenza, Italy.
Instrumental in the introduction of continuous hemofiltration and high flux dialysis in Europe.
Seventeen books on nephrology and dialysis.
350+ scientific papers.
Editorial board of twelve scientific journals.
Director of three international scientific societies.
SCIENCE ADVISORY BOARD / Dialysis
Trading Symbol: AEMD
Larry Cowgill, D.V.M., Ph.D.
Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California.
Head of companion animal dialysis at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego.
Leading authority in managing animal dialysis clinical programs.
SCIENCE ADVISORY BOARD / Dialysis
Trading Symbol: AEMD
Raveendran Pottathil, Ph.D.
Former Section Director of Retroviral Research at Hoffman La Roche.
Advisor to World Health Organization’s Sexually Transmitted Diseases and Global Vaccination Program.
Co-founder of Specialty Biosystems, Inc. President of AccuDx, Inc.
SCIENCE ADVISORY BOARD / Infectious Disease
Trading Symbol: AEMD
Jean-Claude Chermann, Ph.D.
AIDS virus discoverer.
Director of Research of the Pasteur Institute. Director of Research of INSERM (French National Institute of
Health and Medical Research).
First to demonstrate that HIV is a retrovirus.
First use of HIV anti-retroviral agent in humans.
First to demonstrate HIV infection in US patients through the detection of antibodies.
SCIENCE ADVISORY BOARD / Infectious Disease
Trading Symbol: AEMD
Pedro Cuatrecasas, MD
Inventor of Affinity Chromatography.
Former President of Pharmaceutical Research at Parke-Davis.
Corporate Vice President for Warner Lambert Company.
Senior Vice President and Director of Glaxo Inc.
Vice President, R&D, and Director, of Burroughs Wellcome.
Involved in the commercialization of over forty novel medicines.
Member of the National Academy of Sciences, The Institute of Medicine, American Academy of Arts & Sciences.
Numerous awards, including The Wolf Prize in Medicine.
400+ scientific publications.
SCIENCE ADVISORY BOARD / Infectious Disease
Trading Symbol: AEMD
Targeted 12-Month Value Drivers
Introduction of Aethlon to the Financial Industry
Partnerships
Biowarfare Animal Data
Human Trial Initiation
Grant Income
Trading Symbol: AEMD
Investment Data
OTCBB: “AEMD”
Stock Price (3/26/04): $1.85
Market Capitalization (3/26/04) : $16.9 million
Shares Outstanding (2/12/04): 9,122,711
Trading Symbol: AEMD
Conclusion
NOT IF, BUT WHEN
top related